ATE295722T1 - Zielgerichtete liposomen zur verabreichung von genen - Google Patents

Zielgerichtete liposomen zur verabreichung von genen

Info

Publication number
ATE295722T1
ATE295722T1 AT98958643T AT98958643T ATE295722T1 AT E295722 T1 ATE295722 T1 AT E295722T1 AT 98958643 T AT98958643 T AT 98958643T AT 98958643 T AT98958643 T AT 98958643T AT E295722 T1 ATE295722 T1 AT E295722T1
Authority
AT
Austria
Prior art keywords
targeted liposomes
gene administration
virus
gene
administration
Prior art date
Application number
AT98958643T
Other languages
English (en)
Inventor
Esther H Chang
Liang Xu
Kathleen Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE295722T1 publication Critical patent/ATE295722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT98958643T 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen ATE295722T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6618897P 1997-11-19 1997-11-19
US8317598P 1998-04-27 1998-04-27
PCT/US1998/024657 WO1999025320A1 (en) 1997-11-19 1998-11-19 Targeted liposome gene delivery

Publications (1)

Publication Number Publication Date
ATE295722T1 true ATE295722T1 (de) 2005-06-15

Family

ID=26746455

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98958643T ATE295722T1 (de) 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen
AT01123562T ATE459340T1 (de) 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01123562T ATE459340T1 (de) 1997-11-19 1998-11-19 Zielgerichtete liposomen zur verabreichung von genen

Country Status (12)

Country Link
EP (2) EP1166775B1 (de)
JP (2) JP2001522871A (de)
CN (3) CN1616665B (de)
AT (2) ATE295722T1 (de)
AU (1) AU759164C (de)
CA (1) CA2308584C (de)
DE (2) DE69841536D1 (de)
DK (1) DK1166775T3 (de)
ES (1) ES2339421T3 (de)
HK (1) HK1045641B (de)
PT (1) PT1166775E (de)
WO (1) WO1999025320A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1811036E (pt) 1999-02-22 2011-07-11 Univ Georgetown Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes
US9034330B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2004066908A2 (fr) * 2003-01-17 2004-08-12 Sanofi Pasteur Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee
CA2513769A1 (en) * 2003-01-28 2004-08-12 Georgetown University Method for evaluating the efficacy of certain cancer treatments
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
AU2004251680B2 (en) * 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
JP5102630B2 (ja) * 2005-11-24 2012-12-19 ジェノミディア株式会社 改変パラミクソウイルスおよびその作製方法
CN102133404B (zh) * 2011-03-23 2013-01-16 成都诺恩生物科技有限公司 一种肿瘤靶向治疗药物载体、其制备方法及其应用
MX2014007664A (es) 2011-12-22 2015-05-11 Nuvo Res Gmbh Composiciones liposomicas de clorito o clorato.
CN103655475B (zh) 2012-09-19 2020-04-28 乔治敦大学 靶向的脂质体
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2901616A1 (en) 2013-03-14 2014-10-02 Georgetown University Treatment for exposure to nerve agent
US10709761B2 (en) 2015-10-08 2020-07-14 University Of Utah Research Foundation Methods and compositions for preventing or treating cancer
EP3538546B1 (de) 2016-11-14 2025-01-08 Novartis AG Zusammensetzungen, methoden und therapeutische verwendungen des fusogenen proteins minion
WO2020077039A1 (en) 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
WO1996008263A1 (en) * 1994-09-13 1996-03-21 Theratech, Inc. Intracellular delivery of chemical agents to a specific cell type
US20020051767A1 (en) * 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
ATE333892T1 (de) * 1996-02-09 2006-08-15 Pi-Wan Cheng Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体

Also Published As

Publication number Publication date
PT1166775E (pt) 2010-04-16
HK1045641B (en) 2010-10-29
EP1032369A1 (de) 2000-09-06
AU759164B2 (en) 2003-04-10
DE69841536D1 (de) 2010-04-15
DE69830249T2 (de) 2006-05-04
CN1616665A (zh) 2005-05-18
CN1286630A (zh) 2001-03-07
CN1191094C (zh) 2005-03-02
EP1032369B1 (de) 2005-05-18
EP1166775A3 (de) 2003-06-25
DK1166775T3 (da) 2010-05-03
HK1078608A1 (en) 2006-03-17
WO1999025320A1 (en) 1999-05-27
AU1464299A (en) 1999-06-07
EP1166775B1 (de) 2010-03-03
AU759164C (en) 2007-03-29
CA2308584C (en) 2011-07-19
CA2308584A1 (en) 1999-05-27
HK1045641A1 (en) 2002-12-06
JP2001522871A (ja) 2001-11-20
CN1616665B (zh) 2010-10-06
CN1904055A (zh) 2007-01-31
DE69830249D1 (de) 2005-06-23
HK1035490A1 (en) 2001-11-30
EP1166775A2 (de) 2002-01-02
JP2010263920A (ja) 2010-11-25
ATE459340T1 (de) 2010-03-15
ES2339421T3 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
ATE459340T1 (de) Zielgerichtete liposomen zur verabreichung von genen
ATE273320T1 (de) Fusogene liposomen
ATE172636T1 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
AU9676198A (en) Drug delivery and gene therapy delivery system
NO994837L (no) Intravesikal medikamentavleveringssystem
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
MX9800719A (es) Proteinas de transporte y sus usos.
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
WO2001080840A3 (en) Cytotoxic agents comprising single-stranded and/or looped dna
WO2003002142A8 (fr) Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques
ATE322255T1 (de) Polyamid-oligomere
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
ATE391186T1 (de) Gezielte verabreichung von kuenstlichen genen
ID29405A (id) Protein antigen tumor sart-3 yang baru dan peptida-peptida antigen tumornya
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
WO1999065461A3 (en) Cationic amphiphile micellar complexes
NO20020604L (no) Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning
EP1041146A4 (de) Tumorantigen protein, dafür kodierendes gen und dessen verwendung
ATE55618T1 (de) Gene fuer biologisch aktive proteine.
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties